Propofol Regulates ER Stress to Inhibit Tumour Growth and Sensitize Osteosarcoma to Doxorubicin
Osteosarcoma is the most common malignant bone tumour affecting children and young adults. The antitumour role of propofol, a widely used intravenous sedative-hypnotic agent, has been recently reported in different cancer types. In this study, we aimed to assess the role of propofol on osteosarcoma...
Saved in:
Main Authors: | Hua Wei, Xinhui Du, Huaping Zhao, Peipei Sun, Jianjun Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | International Journal of Clinical Practice |
Online Access: | http://dx.doi.org/10.1155/2023/3093945 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A detoxified TLR4 agonist inhibits tumour growth and lung metastasis of osteosarcoma by promoting CD8+ cytotoxic lymphocyte infiltration
by: Ryunosuke Oyama, et al.
Published: (2025-01-01) -
The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
by: Saba Dadpour, et al.
Published: (2022-09-01) -
Inhibition of id-1 reduces osteosarcoma growth and metastasis through mediation of snail
by: Rongbing Shu, et al.
Published: (2025-01-01) -
IFN-γ reprograms cardiac microvascular endothelial cells to mediate doxorubicin transport and influences the sensitivity of mice to doxorubicin-induced cardiotoxicity
by: Haoyu Ji, et al.
Published: (2025-01-01) -
Prednisone inhibits osteosarcoma cell by regulating the Wnt/β-catenin signaling pathway
by: Yo Zhang, et al.
Published: (2024-12-01)